Year: 2026

Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026

Written by Customer Service on March 30, 2026. Posted in Public Companies.

Can-Fite Signed a Deal Worth up to $325M with the Veterinary Company Vetbiolix Ramat Gan, Israel, March 30, 2026 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that its veterinary partner Vetbiolix has completed enrollment in a Phase 2 study of Piclidenoson for the treatment of osteoarthritis in dogs. Vetbiolix, Can-Fite’s veterinary commercialization partner, is funding all development costs associated with the registration of Piclidenoson for osteoarthritis in companion animals. The randomized, double-blind, placebo-controlled, dose-ranging Phase 2 clinical study is evaluating 118 client-owned dogs with osteoarthritis treated with Piclidenoson over...

Appili Therapeutics to Exhibit at World Vaccine Congress Washington

Written by Customer Service on March 30, 2026. Posted in Public Companies.

Appili Presentation Highlights Recent Collaborations and Funding Milestones Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities HALIFAX, Nova Scotia, March 30, 2026 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that President and Chief Executive Officer Dr. Don Cilla and Chief Development Officer, Dr. Gary Nabors will exhibit at the World Vaccine Congress Washington 2026. “The World Vaccine Congress Washington provides an important venue to engage with global vaccine experts and government leaders,” said Dr. Cilla, President and CEO of Appili Therapeutics. “At the congress, Appili will be focused...

Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

Written by Customer Service on March 30, 2026. Posted in Public Companies.

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. JNJ‑4804 is a novel co‑antibody therapy that blocks the complementary interleukin‑23 (IL‑23) and tumor necrosis factor (TNF) pathways, delivering synergistic effects on the pathogenesis of chronic immune‑mediated diseases. “We are delighted to collaborate with Johnson & Johnson on the clinical development of JNJ-4804,” said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. “Royalty Pharma has a strong track record of investing in immunology, beginning with early disease-modifying...

Bayport Management Ltd Standalone Financial Statements year ended December 2025

Written by Customer Service on March 30, 2026. Posted in Public Companies.

Bayport Management Ltd Standalone Financial Statements year ended December 2025AttachmentSigned AFS – BML Standalone 31 Dec 2025

Bayport Management Ltd Group Audited Financial Statements year ended December 2025

Written by Customer Service on March 30, 2026. Posted in Public Companies.

Bayport Management Ltd Group Audited Financial Statements year ended December 2025AttachmentSigned AFS – BML Group 31 Dec 2025

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Written by Customer Service on March 30, 2026. Posted in Earnings Releases And Operating Results.

Oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026Commercial readiness activities ongoing in anticipation of potential commercial launch of OLC in 3Q26As of March 30, 2026 unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, with expected runway into 2027LOS ALTOS, Calif., March 30, 2026 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended December 31, 2025, and provided a business update. “This year is shaping up to be pivotal for Unicycive, underscored by the U.S. Food and...

PMGC Holdings Inc. [NASDAQ: ELAB] Reports 2025 Annual Results and Files Form 10-K, Company Expands Asset Base to $13.8M, a 43% Increase from 2024

Written by Customer Service on March 30, 2026. Posted in Earnings Releases And Operating Results.

Deploys Capital into Cash-Flowing Manufacturing Businesses in Aerospace, Defense and IT Packaging Advances Dual Myostatin Assets Targeting Muscle Preservation in Potential Combination with GLP-1 TreatmentsNEWPORT BEACH, Calif., March 30, 2026 (GLOBE NEWSWIRE) — PMGC Holdings Inc. (NASDAQ: ELAB) (“the Company,” “PMGC,” “we,” or “our”) today filed its Annual Report on Form 10-K (“Annual Report”) for the fiscal year ended December 31, 2025 (“FYE 2025”), with the U.S. Securities and Exchange Commission (“SEC”). The Annual Report is available on the SEC’s website at www.sec.gov under the Company’s filings and on the Company’s investor relations website. A Year of Capital Allocation and Asset Growth Fiscal 2025 marked a year of disciplined capital deployment and balance sheet expansion.Total assets increased 43%, from approximately...

Priority Income Fund Announces 16.6% Annualized Total Cash Distribution Rate (on Net Asset Value) with Common Shareholder Distributions for March 2026 through May 2026

Written by Customer Service on March 30, 2026. Posted in Dividend Reports And Estimates.

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) — Priority Income Fund, Inc. (“Priority Income Fund” or the “Fund”) announced today that the Fund’s Board of Directors has declared monthly cash common shareholder distributions for March 2026, April 2026, and May 2026. The annualized total cash distribution is $0.70000 per share (16.6% annualized rate based on the February 28, 2026 net asset value), for distributions with record dates between March 27, 2026 and May 5, 2026 based on the February 28, 2026 net asset value of $4.22 per common share. The cash distributions will have monthly record dates and will be payable monthly to common stockholders of record at the close of business each month. These declared distributions equal a monthly cash amount of $0.05833 per share of common stock (or $0.17499 on a quarterly basis) as follows:Monthly...

Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Written by Customer Service on March 30, 2026. Posted in Earnings Releases And Operating Results.

New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies KOASTAL-2 and -3 fully enrolled in the first quarter of 2026; on track for topline readout in the second quarter of 2026 NMRA-898 selected as lead program in M4 franchise based on promising clinical results from ongoing Phase 1 study Strong financial position with $182.5 million in cash, cash equivalents and marketable securities expected to support operations into the third quarter of 2027 Company to host conference call today at 8:00 a.m. ET WATERTOWN, Mass., March 30, 2026 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved,...

Sysco to Acquire Jetro Restaurant Depot to Expand into Higher-Margin, Growing, and Resilient Cash & Carry Channel

Written by Customer Service on March 30, 2026. Posted in Mergers And Acquisitions.

Transaction Combines Two Complementary Food-Away-From-Home Industry Leaders to Create Preeminent U.S. Multi-Channel Foodservice Distribution Platform Transaction Expected to be Immediately Accretive to Margins, EPS, and Free Cash Flow and Deliver Synergies Cash & Carry is a Large, Growing, Attractive, and Complementary Channel Serving Smaller Independent Foodservice Customers Combined Company Will Be More Profitable and Return More Value to Shareholders Combined Company to Enhance Value for Small Businesses and the Consumers They Serve by Expanding Access to More Affordable Products and Delivering More Choice and Convenience Jetro Restaurant Depot to Operate as a Standalone Business Segment Within Sysco Sysco Reaffirms Full Year 2026 Guidance; Q3 2026 USFS Local Volume Growth of Over 3.0% Sysco to Host Investor Conference Call Today...

Year: 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals